Skip to main content
. 2022 Oct 21;7(43):38193–38206. doi: 10.1021/acsomega.2c05296

Table 4a. Experimental Conditions of Methodologies to Analyze Peptides Used in Doping.

Analyte Guide Experimental conditions Matrix/pretreatment procedure
GHRPs and GHSs WADA ISO/IEC 17025 RP-HPLC, Kinetex C18 column (100 mm × 2.1 mm, 2.6 μm), mobile phase A (0.1% FA in water), B (0.1% FA in ACN), temperature oven 35 °C, flow rate 0.5 mL/min; 5/95/95/5/5% B in 0.5/5.5/6.5/8.0 min; LC–MS/MS conditions: ESI-triple quadrupole, ion spray voltages: 4.5 kV in positive mode; capillary and vaporizer temperatures: 320 °C, sheath and auxiliary gas flow rate: 60 arbitrary units, respectively97 matrix: urine; pretreatment sample: IE/RP-SPE97
mixture of peptides used in doping ISO-17025 RP-HPLC, ACQUITY UPLC CSH C18 column (100 × 1 mm2, 1.7 μm), 210 nm, mobile phase A (0.1% FA in water), B (0.1% FA in ACN), temperature oven: 35 °C, flow rate: 0.3 mL/min; 2/2/24/30/50/99/99/2/2% B in 1/2/13/21/23/24/26/27/32 min; screening: UPLC-DAD, ESI-IT, mode positive, spray voltage: 4.5 kV, end plate voltage: 500 V; nebulizer 2 bar, desolvation gas temperature: 250 °C at a flow rate: 10 L/min101 matrix: water; pretreatment sample: centrifugation101
mixture of peptides used in doping WADA UHPLC, HF-X Hybrid Quadrupole-Orbitrap, A Poroshell 120 EC-C8 analytical column (3 × 50 mm, 2.7 μm), mobile phase A (0.1% FA in water), B (0.1% FA, 1% DMSO in ACN), temperature column: 30 °C, flow rate: 0.35 mL/min; 1/40/90/90/1% B in 1/11/11.5/13/16 min; mode positive, ionization voltage: 3.3 kV90 matrix: blood pretreatment sample: centrifugation90
mixture of peptides used in doping WADA-ISO/IEC 17025 UHPLC, Agilent Poroshell 120 ECC18 column (50 × 2.1 mm, 2.7 μm), mobile phase A (0.2% FA in water), B (0.2% FA in ACN), temperature column: 40 °C, flow rate 0.4 mL/min; 1/1/60/100/1/1% B in 0/1/7/7.1/9.1/9.2/11 min; injection volume: 10 μL, Q-TOF parameters: positive mode, drying and nebulizing gas: nitrogen; drying gas flow: 12 L/min, 250 °C, nebulizer gas pressure: 40 psi, sheath gas flow: 8 L/min, 350 °C; capillary and nozzle voltages were 4000 and 1000 V, respectively55 matrix: urine; pretreatment sample: RP-SPE55
GHRHs N.R. UHPLC, Waters Symmetry trapping column C18 (180 μm × 20 mm, 5 μm), mobile phase A (0.1% FA in water), B (0.1% FA in ACN), flow rate: 350 nL/min; 1/60/80/1/1% B in 0/20/22/23/31 min; Q-Orbitrap parameters: positive mode, transfer capillary temperature: 150 °C, spray voltage: 2 kV102 matrix: plasma; pretreatment sample: immunoaffinity-SPE102
GHRP-6 FDA Nano-HPLC-Q-TOF, monolithic nanocolumn (200 μm × 5 cm) and a trap column (200 μm × 5 mm) from LC Packings, mobile phase A (0.1% FA in water), B (0.1% FA in ACN/water 80/20 v/v), flow rate: 0.8 μL/min; 50/100/100/10% B in 0/2/5/7 min; capillary voltage: 2.5 kV; cone voltage: 40 V103 matrix: human plasma; pretreatment sample: precipitation, centrifugation, and desalting103
IGF-1 WADA-ISO/IEC 17025 UHPLC-Q-Exactive, Kinetex C18 column (100 × 2.1 mm, 2.6 μm), mobile phase A (0.1% FA in water), B (0.1% FA in MeOH), temperature column: 40 °C, flow rate: 300 μL/min; gradient elution 2/2/95/5/5% B in 0/0.5/8.5/10/12.5 min, mode positive, ion spray voltage: 4.5 kV, capillary heaters temperature: 320 °C, probe heaters: 438 °C, sheath gas flow rate: 51 arbitrary units, auxiliary gas flow rate: 14 arbitrary units98 matrix: mouse serum; pretreatment sample: trypsin digestion, IS 15N-IGF-I98
Leuprolide ICH HPLC, HILIC column (150 mm × 2.1 mm, 6 μm), mobile phase [25 mL CH3COONH4 (0.2 M), 320 mL acetic acid (0.522 M) pH 3], 655 mL water/ACN with 1% FA 25/75, v/v, isocratic elution, flow rate: 1.0 mL/min, temperature column: 25 °C; API-triple quadrupole, mode positive; sheath, auxiliary, and ion sweep gas: nitrogen; ion spray voltage: 5.5 kV, capillary temperature: 750 °C100 matrix: human plasma or serum; pretreatment sample: RP-SPE100
desmopressin and vasopressin N.R. RP-HPLC, Pyramid C18 column (50 mm × 2.1 mm, 1.9 μm), mobile phase A (0.1% FA in water), B (ACN), gradient elution: 0/100/100/0/0% B, in 0/8/8.5/9/15 min; flow rate: 0.3 mL/min triple quadrupole-TOF, mode positive at 500 °C; collision and auxiliary/sheath gas nitrogen104 matrix: urine; pretreatment sample: EI-RP-SPE104